• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Phytochemicals targeting lncRNAs: A novel direction for neuroprotection in neurological disorders
Biomed Pharmacother. 2023 Apr 12;162:114692. doi: 10.1016/j.biopha.2023.114692. Online ahead of print.ABSTRACTNeurological disorders with various etiologies impacting the nervous system are prevalent in clinical practice. Long non-coding RNA (lncRNA) molecules are functional RNA molecules exceeding 200 nucleotides in length that do not encode proteins, but participate in essential activities. Research indicates that lncRNAs may contribute to the pathogenesis of neurological disorders, and may be potential targets for their treatment. Phytochemicals in traditional Chinese herbal medicine (CHM) have been found to exert neuro...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 14, 2023 Category: Drugs & Pharmacology Authors: Hang Zhao Lin Wang Lijuan Zhang Hongyu Zhao Source Type: research

The Application of Nanomaterials in Stem Cell Therapy for some Neurological Diseases.
Abstract Stem cell therapy provides great promising therapeutic benefits for various neurological disorders. Cell transplantation has emerged as cell replacement application for nerve damage. Recently, nanomaterials obtain wide development in various industrial and medical fields, and nanoparticles have been applied to neuro-medical field for tracking and treating nervous system diseases. Combining stem cell with nanotechnology has raised more and more attentions; and it has demonstrated that it has huge effects on clinical diagnosis and therapeutics in multiple central nervous system diseases, meanwhile, improvin...
Source: Current Drug Targets - March 28, 2017 Category: Drugs & Pharmacology Authors: Zhang G, Khan AA, Wu H, Chen L, Gu Y, Gu N Tags: Curr Drug Targets Source Type: research

Colchicine in Neurosurgery.
CONCLUSION: Colchicine is a drug that over the years has shown promising results in certain neurosurgical entities. Its derivatives or potential colchicine-like agents might have a more significant place in neurosurgical practice. PMID: 29336254 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - January 14, 2018 Category: Drugs & Pharmacology Authors: Evangelos D, Dimitrios G, Marios TS Tags: Curr Pharm Des Source Type: research

Protective Effects of Alpha-Lipoic Acid on Glutamate-Induced Cytotoxicity in C6 Glioma Cells.
In this study, we investigated the protective effects of alpha-lipoic acid (ALA), a naturally occurring thiol antioxidant, on glutamate-induced cytotoxicity in cultured C6 astroglial cells. Exposure to high-dose glutamate (10 mM) caused oxidative stress and mitochondrial dysfunction through the elevation of reactive oxygen species, depletion of glutathione, and loss of the mitochondrial membrane potential (ΔΨm). Pretreatment with ALA (200 µM), however, significantly inhibited the glutamate-induced oxidative stress and mitochondrial dysfunction. ALA pretreatment dose-dependently suppressed glutamate-induced apoptotic...
Source: Biological and Pharmaceutical Bulletin - January 6, 2019 Category: Drugs & Pharmacology Authors: Park E, Gim J, Kim DK, Kim CS, Chun HS Tags: Biol Pharm Bull Source Type: research

Connecting Metainflammation and Neuroinflammation Through the PTN-MK-RPTP β/ζ Axis: Relevance in Therapeutic Development
Conclusion The expression of the components of the PTN-MK-RPTPβ/ζ axis in immune cells and in inflammatory diseases suggests important roles for this axis in inflammation. Pleiotrophin has been recently identified as a limiting factor of metainflammation, a chronic pathological state that contributes to neuroinflammation and neurodegeneration. Pleiotrophin also seems to potentiate acute neuroinflammation independently of the inflammatory stimulus while MK seems to play different -even opposite- roles in acute neuroinflammation depending on the stimulus. Which are the functions of MK and PTN in chronic neuroi...
Source: Frontiers in Pharmacology - April 11, 2019 Category: Drugs & Pharmacology Source Type: research

Repurposing multiple sclerosis drugs: a review of studies in other neurological and psychiatric conditions.
Abstract Treatment options for multiple sclerosis (MS) have improved in the past 20 years, with new oral disease-modifying drugs and monoclonal antibodies becoming available. The success seen with these drugs in MS, and their various mechanisms of action, has led to them being investigated in other neurological and psychiatric disorders. This review article summarises the ongoing and completed studies of MS drugs in neurological and psychiatric conditions other than MS. The most promising results are for interferon beta in human T cell leukaemia virus 1 associated myelopathy/tropical spastic paraparesis and glioma...
Source: Drug Discovery Today - May 13, 2019 Category: Drugs & Pharmacology Authors: Rommer PS, Sellner J Tags: Drug Discov Today Source Type: research

Recent Strategies for Targeted Brain Drug Delivery.
Abstract Because the brain is the most important human organ, many brain disorders can cause severe symptoms. For example, glioma, one type of brain tumor, is progressive and lethal, while neurodegenerative diseases cause severe disability. Nevertheless, medical treatment for brain diseases remains unsatisfactory, and therefore innovative therapies are desired. However, the development of therapies to treat some cerebral diseases is difficult because the blood-brain barrier (BBB) or blood-brain tumor barrier prevents drugs from entering the brain. Hence, drug delivery system (DDS) strategies are required to delive...
Source: Chemical and Pharmaceutical Bulletin - July 3, 2020 Category: Drugs & Pharmacology Authors: Ogawa K, Kato N, Kawakami S Tags: Chem Pharm Bull (Tokyo) Source Type: research

CDKN2B-AS1: An indispensable long non-coding RNA in multiple diseases.
CONCLUSIONS: Long non-coding RNA CDKN2B-AS1 likely serves as a promising therapeutic target or prognosis biomarker in multiple human diseases. PMID: 32767927 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - August 4, 2020 Category: Drugs & Pharmacology Authors: Song C, Qi Y, Zhang J, Guo C, Yuan C Tags: Curr Pharm Des Source Type: research

An update on the role of miR-124 in the pathogenesis of human disorders.
Abstract MicroRNA-124 (miR-124) is a copious miRNA in the brain, but it is expressed in a wide range of human/animal tissues participating in the pathogenesis of several disorders. Based on its important function in the development of the nervous system, abnormal expression of miR-124 has been detected in nervous system diseases including Alzheimer's disease, Parkinson's disease, Hypoxic-Ischemic Encephalopathy, Huntington's disease, and ischemic stroke. In addition to these conditions, miR-124 contributes to the pathogenesis of cardiovascular disorders, hypertension, and atherosclerosis. Besides, it has been show...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - January 4, 2021 Category: Drugs & Pharmacology Authors: Ghafouri-Fard S, Shoorei H, Bahroudi Z, Abak A, Majidpoor J, Taheri M Tags: Biomed Pharmacother Source Type: research

Clinical effectiveness of sodium fluorescein-guided microsurgery in patients with high-grade gliomas
CONCLUSIONS: Fluorescein-guided microsurgery can dramatically improve total resection rate, postoperative neurological functional status, and overall survival with higher efficacy and safety in patients with high-grade gliomas.PMID:37203814 | DOI:10.26355/eurrev_202305_32296
Source: Pharmacological Reviews - May 19, 2023 Category: Drugs & Pharmacology Authors: G-B Wang W-X Wang J-J Luo Source Type: research

Pages: 1  2